Related Experiment Video
Updated: Jun 30, 2026

Transcorporal Artificial Urinary Sphincter Cuff Placement in a Case Requiring Revision for Urethral Atrophy
Published on: June 16, 2022
Impact of United States Food and Drug Administration Position Statements on Complication Rates Within 30 Days After
Arshia Aalami Harandi1, Natalie Braun2, Jason Kim1
1Department of Urology, Stony Brook University Medical Center, Stony Brook, New York.
Introduction:
The US Food and Drug Administration (FDA) has issued 3 notices regarding the use of synthetic material in stress urinary incontinence (SUI) sling surgeries. In 2011, the FDA published a 15-page report on the use of mesh in SUI procedures, reviewing nearly 4000 cases of adverse events including erosion, infection, pain, and difficulty urinating. This study investigated the impact of these notices on sling placement patterns and their complication rates.
Methods:
This was a retrospective analysis of the American College of Surgeons National Surgical Quality Improvement Program database from 2008 to 2020 with Current Procedural Terminology code 57288. Exclusion criteria included male sex, American Society of Anesthesiology class IV-V, primary surgical specialty other than urology or gynecology, or concurrent major operations (hysterectomy, colpocleisis, rectocele repair, etc).
Results:
Of the 79,536 surgical cases of SUI slings, 41,856 met the study criteria and were included in analysis. In the examined timeframe (2012-2014) following the 2011 FDA statement, there was a significant decline in complications after SUI sling placement and a significant increase in the number of fascial slings. Cases performed after the statement had 18% decreased odds of any complications. Cases performed by urologists had 41% reduced odds of complications compared with those performed by gynecologists. Fascial slings had 4-fold increased odds of complications.
Conclusions:
FDA monitoring and communication regarding implantable synthetics may influence surgical practice and outcomes. Additional study is needed to investigate whether the FDA should have more frequent communication regarding procedures with synthetic implantation.
Insights
The US Food and Drug Administration
Area of Science:
- Urology
- Gynecology
- Surgical Quality Improvement
Background:
- US Food and Drug Administration (FDA) issued notices on synthetic mesh for stress urinary incontinence (SUI) surgery.
- A 2011 FDA report detailed adverse events like erosion, infection, and pain from SUI mesh procedures.
Purpose of the Study:
- To investigate the impact of FDA notices on SUI sling placement and complication rates.
- To analyze changes in surgical practice and patient outcomes following FDA communications.
Main Methods:
- Retrospective analysis of the National Surgical Quality Improvement Program (NSQIP) database (2008-2020).
- Included 41,856 SUI sling procedures (CPT code 57288), excluding specific patient and surgical criteria.
Main Results:
- A significant decline in SUI sling complications was observed post-2011 FDA statement.
- An increase in fascial slings and a decrease in overall complications (18%) occurred.
- Urologist-performed procedures had 41% fewer complications; fascial slings showed 4-fold increased complication odds.
Conclusions:
- FDA monitoring and communication influence surgical practices and outcomes for synthetic implants.
- Further research is needed on the frequency and impact of FDA communication for implantable synthetics.
Related Concept Videos
Drug Regulation
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
FDA Approved Drugs: Changes to Approved Drugs
Cardiac Catheterization IV: Nursing Management

